Issue 87

Kernel Flow

Kernel Flow and the Need for Neuroimaging Data

At PSYCH Symposium: London 2022, Kernel’s Chief Technology Officer, Ryan Field, delivered a presentation on the use of the company’s Kernel Flow device in a Cybin-sponsored feasibility study.

Kernel Flow is a headset that measures brain activity before, during and after the administration of psychedelic medicine, by recording localised changes in blood oxygenation.

Akin to a wearable fMRI scanner, Kernel Flow provides quantifiable neuroimaging data in real-time. To discuss the company’s innovation and how it can be used to accelerate clinical trials, PSYCH sat down with Kernel’s Chief Technology Officer.

READ MORE

US DEPARTMENT OF VETERANS AFFAIRS CONDUCTS STUDIES WITH PSYCHEDELIC MEDICINE

The US Department of Veterans Affairs has launched clinical trials to study the efficacy of psychedelic-assisted therapy to treat PTSD.

Read More

COLORADO ACTIVISTS FILE BALLOT INITIATIVE FOR PSILOCYBIN FRAMEWORK

The Natural Medicine Health Act would create a legal psilocybin market in Colorado, with regulators creating rules for cultivation and sale.

Read More

BUSINESS AND INVESTMENT

COMPASS beats psilocybin patent challenges.

The profitability of training psychedelic therapists.

Virtual reality in psychedelic-assisted therapy.

Red Light Holland to enter Oregon’s psilocybin market.

FDA approves Ceruvia’s Phase II trial for OCD.

FDA clears Cybin’s Phase I/IIa clinical trial.

Nirvana Life Sciences files patent for isolation of psilocin.

Tryp Therapeutics files patent for binge eating treatment.

HAVN enters supply agreement with MPB Group.

Questions for the psychedelic renaissance.

Psychedelic healthcare in Saudi Arabia.

Silo Pharma to target autoimmune disease.

The Psychedelics as Medicine Report provides market intelligence from industry experts and thought leaders.

Previous sponsors include atai Life Sciences, COMPASS Pathways and Cybin.

Contact Grace@psych.global for partnership opportunities.

CONTACT FORM

SCIENCE AND RESEARCH

Biomarkers of antidepressant response to ketamine.

Effect of psychedelic medicines on neurotransmitters.

REGULATION AND LEGISLATION

Leader of New Jersey senate files psilocybin legalisation bill.

Congressional leaders call for psilocybin policy analysis.

Washington activists call off decriminalisation effort.

County in Oregon considers banning psilocybin therapy.

Paul Stamets, David Nutt and David Nichols will discuss rigorous science and psychedelic therapies September 22nd-24th 2022.

Use the code PSYCH100 for €100 off tickets.

TICKETS
Partner with us